U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H20FN3O3
Molecular Weight 357.3788
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DANOFLOXACIN

SMILES

CN1C[C@@H]2C[C@H]1CN2C3=CC4=C(C=C3F)C(=O)C(=CN4C5CC5)C(O)=O

InChI

InChIKey=QMLVECGLEOSESV-RYUDHWBXSA-N
InChI=1S/C19H20FN3O3/c1-21-7-12-4-11(21)8-22(12)17-6-16-13(5-15(17)20)18(24)14(19(25)26)9-23(16)10-2-3-10/h5-6,9-12H,2-4,7-8H2,1H3,(H,25,26)/t11-,12-/m0/s1

HIDE SMILES / InChI

Molecular Formula C19H20FN3O3
Molecular Weight 357.3788
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Danofloxacin is a quinolone antibacterial agent for veterinary medicine. The drug is approved by FDA for the treatment of bovine infectious respiratory disease under the name Advocin (mesylate salt). Danofloxacin exerts its action by inhibiting bacterial DNA gyrase.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
ADVOCIN

PubMed

Sample Use Guides

In Vivo Use Guide
Administered by subcutaneous injection at either 8 mg per kilogram of body weight once or 6 mg per kilogram of body weight with treatment repeated once approximately 48 hours following the first injection.
Route of Administration: Other
In Vitro Use Guide
Danofloxacin minimum inhibitory concentration values (MIC90) were 0.06 ug/mL for both Mannheimia haemolytica and Pasteurella multocida.
Substance Class Chemical
Record UNII
24CU1YS91D
Record Status Validated (UNII)
Record Version